Galapagos Genomics said last week that it has appointed Andre Hoekema as managing director of Galadeno, the company's viral-based discovery and validation business unit.
Hoekema joins Galadeno from Invitrogen, where he was managing director of corporate development Europe. He has also held positions at Molecular Probes Europe, Crucell, DSM Life Sciences, and Genentech. He holds a PhD in physics and mathematics from Leiden University.
Illumina has appointed Paul Grint to its board of directors. Grint is currently senior vice president and chief medical officer of Zephyr Sciences, a biopharmaceutical company. He received his MD from the University of London, St. Bartholomew's Hospital Medical College.
In addition, Illumina said that Scott Kahn has been appointed Vice President and Chief Information Officer. Kahn joins Illumina from Accelrys, where he served as Chief Scientific Officer. Kahn has previously held positions with BioCAD and Molecular Simulations. He has a PhD in theoretical organic chemistry from the University of California, Irvine, and a post doc from Cambridge University, UK. He is a former assistant professor of chemistry at the University of Illinois, Urbana-Champaign.
Illumina has also announced the April 12 resignation of director Scott Greer, an Illumina director since May 2001. Greer is chairman of Abgenics.